MedTrace Logo

PKPD of Rocuronium and Sugammadex Profile in Pediatric Patients

NCT04851574 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2021-04-20

No results posted yet for this study

Summary

The aim of the study is to assess the pharmacokinetic and pharmacodynamic properties of rocuronium and sugammadex and their clinical effect in the terms of both the relaxation of paralysed muscles (rocuronium) and the reversal of neuromuscular blockade (sugammadex) in children over 2 years of age undergoing general anesthesia for surgical procedures needing muscle relaxation for more than 30 minutes.

Conditions

  • General Anesthetic Drug Adverse Reaction

Interventions

DRUG

Sugammadex Injection

Sugammadex was administered in the dose of 0.5 Mg/kg or 1.0 Mg/kg or 2.0 Mg/kg to reverse neuromuscular blockade.

Sponsors & Collaborators

  • Poznan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Alicja Bartkowska-Sniatkowska, MD PhD · Department of Pediatric Anesthesiology and Intensive Care

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-27
Primary Completion
2020-01-20
Completion
2020-01-29

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04851574 on ClinicalTrials.gov